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Abstract
Background Hyperphosphataemia is common and harm-
ful in patients receiving dialysis. Treatment options include
noncalcium-based phosphate binders such as sevelamer
carbonate (SC) and sucroferric oxyhydroxide (PA21).
Objective The aim of this study was to determine the
health economic impact of PA21-based strategies com-
pared with SC-based strategies, from the perspective of the
Scottish National Health Service (NHS).
Methods A Markov model was constructed based on data
from a randomised clinical trial comparing PA21 and SC.
Model input parameters were derived from published lit-
erature, national statistics and unpublished sources. Costs
(price year 2012) and effects were discounted at 3.5 %.
Analysis with a lifelong time horizon yielded the incre-
mental cost-effectiveness ratio (ICER), expressed as cost or
savings per quality-adjusted life-year (QALY) gained or
forgone. Deterministic and probabilistic sensitivity analysis
was performed to explore uncertainties around assumptions
and model input parameters.
Results In the base-case analysis, phosphorus reductions
for PA21 and SC were 1.93 and 1.95 mg/dL. Average
undiscounted survival was estimated to be 7.61 years per
patient in both strategies. PA21 patients accrued less
QALYs (2.826) than SC patients (2.835), partially due to
differential occurrence of side effects. Total costs were
13,119 and 14,728 for PA21 and SC, respectively (dif-
ference per patient of 1609). By using PA21 versus SC,
one would save 174,999 (or 123,463 when including
dialysis and transplantation costs) for one QALY forgone.
A scenario modelling the nonsignificant reduction in mor-
tality (relative risk 0.714) observed in the trial yielded an
ICER for PA21 of 22,621 per QALY gained. In proba-
bilistic sensitivity analysis of the base-case, PA21 was
dominant in 11 %, and at least cost-effective in 53 %, of
iterations, using a threshold of 20,000 per QALY gained.
Conclusions The use of PA21 versus SC in hyperphos-
phataemic patients being intolerant of calcium-based
phosphate binders may be cost saving and yields only very
limited disadvantages in terms of quality-adjusted survival.
PA21 appears to be cost-effective from the perspective of
the Scottish NHS.
Key Points for Decision Makers
Control of hyperphosphataemia in end-stage renal
disease (ESRD) patients receiving maintenance
dialysis is clinically important. Sucroferric
oxyhydroxide (PA21) is a new calcium-free
polynuclear iron(III)-oxyhydroxide phosphate binder
with a high phosphate binding capacity.
In patients receiving maintenance dialysis intolerant
of calcium-based phosphate binders, compared with
sevelamer carbonate treatment PA21 appears to be
cost saving and appears to yield only very limited
disadvantages in terms of quality-adjusted survival
from the perspective of the Scottish National Health
Service.
Due to lack of data, certain assumptions had to be
made. Future studies are needed to provide evidence
of long-term outcomes.
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1 Institute of Pharmaceutical Medicine (ECPM), University of
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Hyperphosphataemia is a commonly encountered problem
in patients with chronic kidney disease (CKD), particularly
in its advanced stages, which occurs because of the
inability of the dysfunctioning kidney to eliminate dietary
phosphorus [1]. Additionally, there is an increased release
of phosphorus from the bone due to dysregulation in cal-
cium balance and hyperparathyroidism.
Hyperphosphataemia has been associated with a variety
of long-term complications and can affect any organ sys-
tem [2]. Prolonged hyperphosphataemia leads to soft-tissue
and vascular calcification. Calcification of coronary arter-
ies, cardiac valves, and pulmonary tissues is associated
with cardiac disease, the leading cause of death in patients
with kidney disease [1]. Therefore, it is important to pre-
vent and treat hyperphosphataemia and maintain serum
phosphorus levels within the recommended ranges.
The mainstay of treatment is dietary phosphorus
restriction [1]; however, many patients require pharmaco-
logic management with phosphate-binding drugs. Cur-
rently available phosphate-binding agents include
aluminium hydroxide, magnesium carbonate, calcium
carbonate (CC), calcium acetate, sevelamer carbonate
(SC), and lanthanum carbonate (LC).
The British Renal Association guidelines recommend
that in patients with kidney disease, serum phosphorus, if
elevated, should be lowered towards the normal range,
between 1.1 and 1.8 mmol/L (3.41–5.57 mg/dL) [3].
In Scotland, first-line treatment of hyperphosphataemia
consists primarily of CC. Patients intolerant of or not
responsive to CC can be treated with a second-line therapy
based on noncalcium-based phosphate binders. SC is a
noncalcium-based phosphate binder and is currently the
market leader in this class [4]. Sucroferric oxyhydroxide
(PA21) is a new calcium-free polynuclear iron(III)-oxy-
hydroxide phosphate binder with a high phosphate binding
capacity [5].
The authors aimed to determine the health economic
impact of PA21 and SC as competing treatment options in
end-stage renal disease (ESRD) patients receiving main-
tenance dialysis and with hyperphosphataemia. PA21 and
SC were compared from the perspective of the Scottish
National Health Service (NHS).
2 Methods
A Markov cohort model was constructed using TreeAge
Pro 2014 Suite (TreeAge Software, Inc., Williamstown,
MA, USA) to assess the cost effectiveness of therapy with
PA21 compared with SC. Given the potentially long-term
consequences of the initial treatment decision, a lifelong
time horizon was used.
2.1 Efficacy and Safety Data
Clinical model inputs were predominantly based on the
efficacy and safety results of the PA-CL-05A/B trial. This
trial studied 1041 (PA21 n = 694, SC n = 347) and 658
(PA21 n = 391, SC n = 267) maintenance dialysis patients
enrolled in the US as well as several European countries,
including Austria, Belgium, Croatia, Czech Republic, Ger-
many, Latvia, Lithuania, Poland, Romania and the UK.
Patients had a history of hyperphosphataemia and of
receiving stable doses of phosphate binders. In the PA-CL-
05A study, subjects were randomised in a 2:1 ratio to either
PA21 or SC, respectively [6]. In both trial arms, study drug
was titrated for safety and efficacy during a 12-week titration
period, and patients then received maintenance treatment for
an additional 12 weeks (stage 1, total duration 24 weeks).
Subjects who completed stage 1 of the PA-CL-05A study at
week 24 and who consented to participate in stage 2
(n = 100) were randomised to receive either PA21 or SC at
the dose administered at the end of week 24, or low-dose
PA21 for 3 weeks. In the PA-CL-05B trial [7], subjects
continued to receive either PA21 or SC as allocated at ran-
domisation into PA-CL-05A [6], at the same dose they were
taking at the end of PA-CL-05A (week 24 for subjects who
only participated in stage 1 and week 27 for subjects who
participated in stage 2). Treatment with PA21 and SC con-
tinued for a further 28 weeks [7]. The primary endpoint was
change in serum phosphorus level. The trial publications by
Floege et al. reported the results of each phase of the trial
separately [6, 7]. Additionally, the second publication
reported efficacy for the entire trial period (phases A and B
combined), but focused on completers only [7]. In contrast,
all PA-CL-05A/B-based parameters used in this analysis
were based on the full analysis set (n = 1041), as available
from a currently unpublished clinical study report.1 In this
set, the PA-CL-05A/B trial (phases A and B combined)
showed overall mean reductions of serum phosphorus of
1.93 mg/dL (95 % confidence interval [CI] 1.78–2.08) and
1.95 mg/dL (95 % CI 1.73–2.17) in the PA21 and SC arms,
respectively (see Footnote 1). These reductions were taken
into account in the base-case analysis. A nonsignificant
survival difference (relative risk [RR] 0.714 for PA21 vs. SC;
95 % CI 0.37–1.40) observed between the trial arms was
taken into account in a scenario analysis (see Footnote 1).
1 Vifor Pharma. Clinical study report. Open-label, randomised,
active-controlled, parallel group, multicentre phase 3 studies to
investigate the long-term safety, tolerability and efficacy of PA21
compared with sevelamer carbonate in dialysis patients with hyper-
phosphataemia. An integrated report for study PA-CL-05A and
extension study PA-CL-05B. May 2013 (personal communication).
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2.2 Structure of the Markov Model
The structure of the Markov model is shown in Fig. 1. The
mortality effect due to elevated serum phosphorus, and the
treatment effect of PA21 and SC on serum phosphorus,
were the two principal mechanisms in the model. Patients
started on either PA21 or SC treatment at a mean serum
phosphorus starting level of 7.59 mg/dL (see Footnote 1).
Initial survival was adapted to account for the increased
risk of mortality associated with a high baseline serum
phosphorus level [8]. The subsequent treatment-induced
risk reduction was based on the mean reductions of phos-
phorus levels observed in the PA21 and SC arms of the PA-
CL-05A/B trial (see Footnote 1), as reported above. The
risk reduction was assumed to apply immediately after the
initiation of treatment. Patients either continued their initial
treatment or switched to the alternative treatment in case of
withdrawal or sustained hyperphosphataemia. These
options are represented by the six mutually exclusive
health states of the model: on-target (patients continue and
achieve target serum phosphorus levels), off-target (pa-
tients remain hyperphosphataemic), alternative treatment
on-target (patients switched to alternative treatment
achieve target phosphorus level), alternative treatment off-
target (patients switched to alternative treatment receive
maximum drug dose but do not achieve target phosphorus
levels), renal transplant (implying the end of hyperphos-
phataemia treatment), and death, with stage transitions at
the end of each cycle. Markov cycle length was set at
1 month and half-cycle correction was implemented as
appropriate. According to the United States Renal Data
System (USRDS) report, the expected remaining lifespan is
approximately 8 years for dialysis patients aged
40–44 years and approximately 4.5 years for those aged
60–64 years [9]. Mean age at model entry was 56 years.
The model adopted a lifetime time horizon represented by
a maximum of 44 years (528 cycles), corresponding to age
100 years. Costs were assessed from the third-party payer
perspective of the Scottish NHS, i.e. indirect costs were not
included. Costs and effects occurring after year 1 were
discounted at 3.5 %. The primary endpoints of this analysis
were undiscounted survival, quality-adjusted life-years
(QALYs), and cost per QALY gained reported as incre-
mental cost-effectiveness ratio (ICER).
2.3 Base-Case Assumptions
The modelled patient cohort was assumed to be intolerant
to calcium-based phosphate binders. Due to high intoler-
ance regarding calcium-based phosphate binders, we
assumed that patients did not switch from a calcium-free to
a calcium-based phosphate binder [10]. For the base-case
analysis, the following additional assumptions were made.
1. The risk of mortality for treated patients was driven by
a mean reduction of serum phosphorus of 1.93 mg/dL
(0.62 mmol/L, conversion factor 0.323) for PA21, and
1.95 mg/dL (0.63 mmol/L, conversion factor 0.323)
for SC (see Footnote 1). RRs of mortality correspond-
ing to these reductions of serum phosphorus levels
were assigned and the resulting changes in mortality
risk were applied to all patients receiving treatment, as
calculation of the underlying average reductions also
included patients who were ‘off-target’, i.e. experi-
enced sustained hyperphosphataemia.
2. It was assumed that after the start of hyperphos-
phataemia treatment, patients were immediately ‘on-
target’ or ‘off-target’.
3. The treatment-specific percentage of withdrawals due
to treatment-emergent adverse events (TEAEs) seen in
the PA-CL-05A/B trial was applied to patients ‘on-
target’ (distributed over 1 year, corresponding to the
trial observation period). ‘On-target’ patients who
withdrew from PA21 or SC due to TEAEs were
assumed to switch to the other drug and were either
‘on-target’ (with treatment continuing at standard
dose) or ‘off-target’ (with treatment continuing at
maximum dose), based on the distribution of treatment
success versus sustained hyperphosphataemia
observed in the trial for each substance.
4. Patients with persistent hyperphosphataemia (‘off-
target’) switched to the other drug during half a year.
After the switch from PA21 to SC, or vice versa,
patients were also either ‘on-target’ (with treatment
continuing at the standard dose) or ‘off-target’ (with
treatment continuing at the maximum dose), according
to the proportions seen in the entire trial (see Footnote
1). The same treatment-specific mean reductions of
serum phosphorus as observed in the trial (see
Footnote 1) were assumed (1.93 mg/dL for PA21 and
1.95 mg/dL for SC).
5. The occurrence of transplantations was set to zero in
the base-case analysis, and dialysis and transplantation
costs were excluded because these costs were not
significantly affected by the choice of phosphate
binder. This decision has a precedent in National
Institute for Health and Care Excellence (NICE)
clinical guideline 157 [11]. The impact of dialysis
and transplantation costs was addressed in a scenario
analysis.
2.4 Model Input Parameters
An overview of all model input parameters, distinguishing
base-case and scenario input parameters, is provided in
Table 1.
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Fig. 1 Decision analysis model. a Structure of the Markov model; b generic structure of the hyperphosphataemia treatment pathway model with
six mutually exclusive health states. PA21 sucroferric oxyhydroxide
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In order to provide a basis for modelling the impact of
PA21 and SC treatment on survival, the following steps
were undertaken (Fig. 2a). First, a Weibull distribution was
defined to reflect the survival curve for patients with a
kidney transplant, as reported in the Scottish Renal Reg-
istry (SRR) report (Table D3.1 in the report) [12]. Subse-
quently, a Weibull distribution [13] reflecting the survival
of patients receiving dialysis, as available from the UK
Annual Renal Registry report (Table 8.10 in the report)
[14], was implemented such that the joint survival curve of
patients receiving dialysis and patients with a kidney
transplant matched the overall survival estimates for all
patients receiving renal replacement therapy, as available
from the SRR report (Table C1.3 in the report) [12].
Importantly, the impact of serum phosphorus levels on
mortality was set to zero before these steps were under-
taken. Because the baseline phosphorus levels in the PA-




















Modelled survival for paents with
kidney transplant
SRR kidney transplant data [12]
Modelled survival for paents with
ESRD
Modelled survival for paents on
dialysis
SRR ESRD data [12]
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Fig. 2 a Survival curves
reflecting survival for patients
with ESRD, patients receiving
dialysis and patients receiving a
kidney transplant that has been
extrapolated from the SRR
report [12] and the UK RRR
[14]. b Survival curves
implemented in the model.
ESRD end-stage renal disease,
SRR Scottish Renal Registry,
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arms, 7.59 mg/dL or 2.45 mmol/L; conversion factor 0.323
(see Footnote 1)) were higher than in the SRR population
(4.86 mg/dL [12]), the ‘starting’ mortality of the modelled
cohort was subsequently adjusted ‘upwards’ to reflect this
difference. It was assumed that for every 1 mg/dL increase
in serum phosphorus, the risk of mortality would increase
by 35 % (RR 1.35; 95 % CI 1.16–1.57), based on a meta-
analysis by Palmer et al. including studies that adequately
controlled for confounding [8]. On this basis, and assuming
the same RR per 1 mg/dL change, the phosphorus level
changes observed in the trial could be applied (Palmer et al.
also reported a second, more conservative estimate of the
increase in mortality risk per 1 mg/dL increase in serum
phosphorus of 1.18 (95 % CI 1.12–1.25), partially based on
less adequately controlled studies. This value was used in a
scenario analysis [8]. The resulting survivor curves are
shown in Fig. 2b.
Utility parameters were derived from published litera-
ture, and the utilities assumed for ESRD on dialysis and
kidney transplantation were 0.57 and 0.81, respectively.
These values were random effects-based pooled weighted
means of EQ-5D questionnaire-based, patient-elicited
utilities from different countries, identified in a systematic
review [15] and reanalysed for NICE guideline 157 [11].
Disutilities for the first month after transplantation and
associated with TEAEs were taken from NICE guideline
157 [11].
Medical resource utilisation estimates of drug use and
average pill burden, maximum daily doses and the use of
dialysis (haemodialysis: 91.9 % [N = 957]; peritoneal
dialysis: 8.1 % [N = 84]) were based on the PA-CL-05A/B
trial (Table 1) [6]. Those patients who switched to the
alternative treatment and were ‘off-target’ were assumed to
receive the maximum daily dose. Patients who were ‘on-
target’ were assumed to receive the mean number of tablets
per day (Table 1). The occurrence of TEAEs of phosphate
binder treatment was derived from the PA-CL-05A/B trial
data [6, 7]. Only AEs with a frequency of at least 2 % were
included in the analyses because the occurrence of infre-
quent AEs could be driven by chance. Probability of
transplantation was derived from the SRR [12].
The costs used in the base-case model are limited to the
costs of both drug therapy and adverse events. British
National Formulary data were used to extract the price for
PA21 and SC [16]. TEAEs were assumed to incur one
general practitioner (GP) appointment each [11] (costs
reported by Curtis [17]). Laboratory and monitoring costs
were the same for PA21 and SC and did not impact the
ICER; therefore, these costs were not included in the
model. Estimates of annual costs of dialysis were derived
from the SRR report and the National Schedule of Refer-
ence Costs [12, 18]. Transplantation costs were estimated
according to the information available from the NHS and
from two publications [19, 20, 21]. Costs (reported in
pounds sterling []) were inflated to 2012 prices as nec-
essary, using the 2012 Pay and Prices Index for hospital
and community health services as estimated by the Per-
sonal Social Services Research Unit (PSSRU) [17].
2.5 Sensitivity Analysis and Scenario Analyses
To assess the influence of parameter uncertainty on model
results, a series of deterministic (DSA) and probabilistic
sensitivity analyses (PSA) were performed. All parameters
underlying uncertainty were varied, with the exception of
the number of GP appointments for adverse events (which
were assumed to be one visit per TEAE, in line with NICE
guideline 157 [11]). Variables were varied by their 95 %
CI or, if unavailable, by ±15 %, as previously in an
analysis comparable to ours [19] (Table 1). PSA (second-
order Monte Carlo simulation) was based on corresponding
distributions (Table 1). Each sensitivity analysis was based
on 10,000 sets of randomly drawn input parameters.
A first scenario analysis replaced the relative mortality
risk estimate of 1.35 per 1 mg/dL increase in serum
phosphorus level with a more conservative estimate of 1.18
[8]. In a second scenario analysis, dialysis and transplan-
tation costs were included in the base-case analysis, while
in a third scenario analysis mortality was modelled dif-
ferently for the PA21 and SC strategies, based on the
nonsignificant RR of mortality (0.714 for PA21 vs. SC;
95 % CI 0.37–1.40) observed between the PA-CL-05A/B
trial arms (see Footnote 1). Taking into account the trial
observation period, this RR was applied for 1 year. The
occurrence of transplantations, as well as dialysis and
transplantation costs, were also included in this scenario. A
fourth scenario analysis assessed the impact of increasing
the costs of diarrhoea (1500 instead of 36), an adverse
event that was more common in the PA21 strategy. A fifth
scenario analysis with an extreme assumption was added to
gain an understanding of the potential impact of our
assumption that patients would switch from PA21 to SC, or
from SC to PA21, due to TEAEs or sustained hyperphos-
phataemia. In this analysis, patients were assumed (coun-
terfactually, we expect) to remain untreated after
withdrawal from their initial treatment.
3 Results
3.1 Base-Case Analysis
The average survival was estimated to be 7.61 years
(undiscounted) per patient in both strategies. During the
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analysis period of 44 years, patients in the PA21 strategy
gained 2.826 QALYs, i.e. 0.009 QALYs less than in the SC
strategy (2.835 QALYs) (Table 2). This small difference
was partially due to the impact of TEAEs in the PA-CL-
05A/B trial (Table 1). Differences in the frequency of
occurrence of TEAEs between the trial arms were signifi-
cant for diarrhoea, nausea and constipation, and non-
significant for abdominal pain and vomiting. Total costs
were 13,119 and 14,728 in the PA21 and SC strategies,
respectively (cost difference per patient of 1609). By
using PA21 versus SC, one would save 174,999 for one
QALY forgone.
3.2 Sensitivity Analysis
DSA was carried out to characterise the robustness of the
base-case results, given parameter uncertainty (Fig. 3).
Varying the mean number of tablets per day in the SC
strategy had the highest impact on the ICER. The second
most influential parameter was the number of tablets per
day in the PA21 strategy, followed by drug cost per tablet
(both strategies) and change in serum phosphorus level
(both strategies). None of the remaining parameters, taken
by themselves, had a significant impact on the ICER.
The PSA results showed mean costs of 14,428 for
PA21 and 16,250 for SC [range PA21 755–41,989; SC
683–50,706]. Mean QALYs were 3.111 for PA21 and
3.126 for SC [range PA21 0.155–8.991; SC 0.147–9.599].
The mean effect difference was 0.015 QALYs. In 11 % of
iterations, PA21 dominated SC, and in 53 % of iterations it
was at least cost-effective, using a threshold of 20,000 per
QALY gained. A corresponding cost-effectiveness scat-
terplot and acceptability curve are shown in Fig. 4a. The
scatterplot confirms the finding of a cost advantage for
PA21, but no clear advantage for either treatment in terms
of clinical effectiveness; it indicates a substantial degree of
uncertainty.
3.3 Scenario Analyses
In the first scenario analysis, the lower relative mortality
risk estimate of 1.18 per 1 mg/dL increase in serum
phosphorus level reduced the cost difference between
PA21 (10,384) and SC (11,658) to 1274, and the dif-
ference in effectiveness to 0.005 QALYs (PA21 2.239, SC
2.244). The PA21 strategy would save 297,940 for one
QALY forgone over a lifelong time horizon.
In the second scenario analysis, the base-case analysis
was repeated but the occurrence of transplantations was
now modelled and dialysis and transplantation costs were
included. As previously, PA21 was less expensive than SC
(131,925 vs. 133,461; difference of 1536), but less
QALYs were gained with PA21 than with SC (5.045
QALYs vs. 5.057 QALYs; difference of 0.012 QALYs).
By using the PA21 strategy, one would save 123,463 for
one QALY forgone over a lifelong time horizon.
In the third scenario analysis, the difference in effec-
tiveness between the PA21 and SC strategies was based on
the nonsignificant RR of mortality (RR 0.714 for PA21 vs.
SC) observed between the PA-CL-05A/B trial arms. In this
scenario, the PA21 strategy was more expensive and
accrued more QALYs than the SC strategy. Total costs
amounted to 92,149 and 86,908 in the PA21 and SC
strategies, respectively, resulting in a cost difference of
5241 over a lifelong time horizon. The gain in QALYs
was 3.545 versus 3.313 (difference of 0.232) in favour of
PA21. In this scenario, the ICER for PA21 compared with
SC was 22,621. In 3 % of scenarios, PA21 dominated SC,
and in 27 % of scenarios it was cost-effective (Fig. 5).
In the fourth scenario analysis, diarrhoea costs were
increased to 1500. The cost difference is lower than in the
base-case analysis (15,811 vs. 14,149; difference of
338) and the difference in QALYs is the same (0.009) as
in the base-case analysis (2.826 QALYs for PA21 vs. 2.835
QALYs for SC). By using the PA21 strategy, one would
Table 2 Costs and quality-adjusted life-years obtained for the base-case and scenario analyses





(0.714) of mortality (GBP)
Scenario analysis of
adverse event costs (GBP)
PA21 SC D PA21 SC D PA21 SC D PA21 SC D
Drug costs 12,969 14,590 -1621 9845 11,086 -1241 6818 7194 -376 12,969 14,590 -1621
Adverse event costs 150 138 12 114 105 9 79 68 11 2842 1561 1282
Transplantation costs – – – 34,414 34,497 -83 24,296 22,720 1576 – – –
Dialysis costs – – – 87,552 87,773 -220 60,956 56,926 4030 – – –
Total costs 13,119 14,728 -1609 131,925 133,461 -1536 92,149 86,908 5241 15,811 16,149 -338
QALYs 2.826 2.835 -0.009 5.045 5.057 -0.012 3.545 3.313 0.232 2.826 2.835 -0.009
Costs are rounded values
GBP Great Britain pound, PA21 sucroferric oxyhydroxide, SC sevelamer carbonate, QALYs quality-adjusted life-years
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save less (170,030) for one QALY forgone over a lifelong
time horizon compared with the base-case (36,810 vs.
174,999).
In the scenario analysis with the extreme assumption
that patients with TEAEs or sustained hyperphosphataemia
would remain untreated after withdrawal from their initial
treatment, the total costs for PA21 were lower than the total
costs for SC, and the difference in costs was higher than in
the base-case (9058 vs. 12,929; difference of 3871).
The gain in QALYs was lower for both strategies com-
pared with the base-case, but slightly more QALYs were
gained with the SC strategy compared with the PA21
strategy (2.679 QALYs for SC and 2.533 QALYs for
PA21). By using the PA21 strategy, one would save less for
one QALY forgone over a lifelong time horizon compared
wtih the base-case (26,515 vs. 174,999).
4 Discussion
In ESRD patients receiving maintenance dialysis, over a
lifelong time horizon, a PA21-based treatment strategy
appears to incur lower costs than SC-based treatment, from
the perspective of the Scottish NHS. QALYs accrued in the
base-case model were marginally lower for the PA21
strategy. By using the PA21 strategy, one would save
174,999 (or 123,463 when including dialysis and trans-
plantation costs) for one QALY forgone. The underlying
small QALY loss is partially driven by differences in
TEAE occurrence between treatment strategies. When
modelling the nonsignificant reduction in mortality (RR
0.714 for PA21 vs. SC) observed in the PA-CL-05A/B trial
in a scenario analysis, the PA21 strategy accrued more
QALYs and was more expensive than the SC strategy,
leading to an ICER of 22,621. The relative increase in
costs on the PA21 side was due to improved survival and
hence longer times on hyperphosphataemia and renal
replacement therapy.
Additional sensitivity and scenario analyses generally
confirmed these observations but indicated a substantial
degree of uncertainty due to sensitivity to some model
parameters. The DSA showed that pill burden, while being
a serious problem for patient adherence [22, 23], also
substantially impacted the ICER over a patient’s lifetime.
Also influential were the drug costs of PA21 and SC, as
well as the change in mean serum phosphorus level
(Fig. 3). Importantly, the model was not sensitive to
changes in the number of withdrawals, health state utilities,
utility decrements, proportion of patients with sustained
hyperphosphataemia, or occurrence of TEAEs. Assuming a
lower impact of serum phosphorus level change on mor-
tality did not alter the direction of the results. Including the
occurrence of transplantations, as well as costs for dialysis
and transplantation, resulted in higher total costs, but an
unchanged cost difference and similar QALYs accrued for
both treatment strategies. The same trend was seen when a
500 % increase in AE costs was assumed (Table 2).
Calcium-based binders have been the standard of care in
phosphate-binding therapy for many years [24]. In cases









































Change in serum phosphorus level PA21 (1.78-2.08)
Change in serum phosphorus level SC (1.73-2.17)
Drug cost per tablet PA21 (1.69-2.29)
Drug cost per tablet SC (0.79-1.07)
Mean number of tablets per day of PA21  (2.0-4.6)
Mean number of tablets per day of SC (5-12)
ICER (in GBP/QALY)
Base-case: GBP 174,999 saved with PA21 per QALY forgone Fig. 3 Tornado diagram of
deterministic sensitivity
analysis addressing the impact
of parameter uncertainty. GBP
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hypercalcaemic patients), noncalcium phosphate binders
are recommended for use [24]. In terms of clinical effec-
tiveness, there is evidence that SC is able to achieve similar
reductions in serum phosphorus levels as CC, with a sim-
ilar pill burden [25, 26]. Some reports have addressed the
cost effectiveness of other noncalcium phosphate binders
[27–32] but the current analysis is the first to assess the cost
effectiveness of the novel drug PA21 in the treatment of
hyperphosphataemia. The majority of data inputs could
also be applied to the UK and therefore we believe that
there would not be a big difference between our results and
the results of a cost-effectiveness analysis performed from
the perspective of the NHS in the UK.
Future research, ideally based on long-term observation,
should focus on a possible association of reduced pill
burden with improved compliance and adherence and
resulting clinical effects, an aspect that could not be con-







of 10,000 bootstrap iterations
for incremental cost and
incremental effectiveness.
Every dot represents one
iteration of the simulation, and
95 % of iterations are depicted
in the circle. Parameters were
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been addressed elsewhere [33]. The existence of differ-
ences in adherence between different phosphate binders
and associated effects on clinical outcomes should be
assessed in a real-life setting.
Our study has a number of limitations. The data sources
available to us were limited in scope. Some assumptions
had to be made where no data were available. In the study
by Floege et al. [7], the mean reduction of serum phos-
phorus level was presented for completers of the PA-CL-
05A/B trial. Therefore, efficacy data for the cost-effec-
tiveness analysis were obtained from the unpublished
clinical study report (see Footnote 1), which covers the full
analysis set. In this analysis set, the mean reduction of
serum phosphorus levels was slightly higher for SC than
for PA21. This renders our cost-effectiveness analysis
more conservative than if the values for completers
reported in Floege et al. [7] had been used (the mean
reduction of serum phosphorus levels in completers was
higher for PA21 than for SC). The proportions of patients
‘on-target’ versus ‘off-target’, as well as the withdrawal
rates observed in the PA-CL-05A/B trial [6, 7], on which
our results are based, may differ from those to be expected
under real-world conditions. We did not include other
phosphate binders in our cost-effectiveness analysis
because SC was the only phosphate binder being compared
with PA21 in a head-to-head trial. In current clinical
practice, combination therapy with phosphate binders is
common [34, 35]; however, published data on how dif-
ferent phosphate binders should exactly be combined and
what the clinical implications would be is rather vague
[11]. A strategy combining PA21 and SC in the same
patient and at the same time could not be modelled without
introducing an uncontrollable amount of uncertainty.
Therefore, we decided to only model strategies represent-
ing monotherapy, with a possibility of switching to the
alternative treatment in the case of nonresponse or with-
drawal due to TEAEs. After switching, the same treatment-
specific efficacy as observed in the trial (reduction in serum
phosphorus levels, 1.93 mg/dL for PA21 and 1.95 mg/dL
for SC) was assumed due to a lack of published data. In the
case of continued nonresponse, administration of the
maximum recommended dose was assumed. The assumed
patient pathway may not fully reflect routine practice.
Under the extreme assumption that patients would remain
untreated after withdrawal from their initial treatment, the
savings for one QALY forgone by using the PA21 strategy
were reduced to 26,515 in comparison with 174,999 in
the base-case analysis. PA21 was disfavoured here due to
the higher withdrawal rates than for SC observed in the
PA-CL-05A/B trial. However, given the long-term com-
plications of hyperphosphataemia, we expect the assump-
tion of no further treatment after withdrawal from PA21 or
SC to be counterfactual for most patients. Cardiovascular
calcification negatively impacts on cardiovascular risk and
contributes to mortality in ESRD patients [36]. SC has been
shown to slow down the progression of cardiovascular
calcification compared with calcium-based phosphate bin-
ders [37]. As PA21 is also a calcium-free phosphate binder
and has shown a nonsignificant survival advantage com-
pared with SC (RR of mortality 0.714; 95 % CI 0.37–1.40),
Fig. 5 Cost-effectiveness
scatterplot (scenario analysis) of
10,000 bootstrap iterations for
incremental cost and
incremental effectiveness.
Every dot represents one
iteration of the simulation. 95 %
of iterations are depicted in the
circle. Parameters were
simultaneously and randomly
sampled from the probabilities,
cost and outcome distributions
for each strategy to account for
uncertainty in the base-case
parameter estimates
(probabilistic sensitivity




1322 F. S. Gutzwiller et al.
we assumed PA21 to be noninferior to SC with respect to
positive effects on cardiovascular calcification, cardiovas-
cular risk and survival not directly driven by the reduction
in serum phosphorus. This was a prerequisite of building
our base-case analysis on the change in serum phosphorus
levels observed in the trial. Our base-case analysis did not
include costs of dialysis and transplantation. However,
these costs were close to equivalent in the two treatment
strategies, as shown in a scenario analysis. This might also
be the case for other costs caused by conditions that are not
influenced by the reduction in serum phosphorus level.
Because comorbidities and concomitant medications were
not reported in the clinical trial publications [6, 7], it was
difficult to assess the comparability of patients in the
clinical trial and patients in Scotland. However, in the
unpublished study report, it was reported that the propor-
tion of patients with cardiac disorders was similar in both
treatment arms and no significant differences regarding
concomitant medications were reported. Due to a lack of
data regarding cardiovascular event risks, we could not
assess the number of avoided cardiovascular events based
on the reduction in serum phosphorus level. However,
because the difference in the mean reduction of serum
phosphorus levels was low, we assumed that the effect of
PA21 versus SC on the occurrence of cardiovascular events
would be limited.
5 Conclusions
The use of PA21 in patients with hyperphosphataemia and
intolerant to calcium-based phosphate binders may be cost
saving when compared with SC, and yields only very
limited disadvantages in terms of quality-adjusted survival.
PA21 appears to be cost-effective from the perspective of
the Scottish NHS.
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